Medicine & Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medicine & Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Alvine Pharmaceuticals
Alvine Pharmaceuticals closes a $21 million series A financing
October 13th, 2006
Alvine Pharmaceuticals, Inc., a biopharmaceutical company focused on developing pharmaceutical products for the treatment of celiac sprue, announced the closing of a $21 million Series A financing. Sofinnova Ventures led the investment round with strong support from Prospect Venture Partners and InterWest Partners. Cargill Ventures and Flagship Ventures also participated in the financing. "This financing brings together a premier group of investors committed to advancing the company's lead product candidate ALV001 into human clinical and safety trials," said Stanford professor Chaitan Khosla, PhD, who co-founded the company. "Celiac sprue is a...
Source: Medicine & Law Weekly (2006-10-13)
|
